Single-cell analysis reveals immune evasion pathways in thyroid cancer metastasis
This study identifies LAG3 and TIGIT as critical immune checkpoints in thyroid cancer, challenging the efficacy of PD-1 blockade.
Phase III
thyroid cancer patients
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of LAG3 and TIGIT as critical immune checkpoints in thyroid cancer suggests that current PD-1 blockade therapies may be ineffective, necessitating a shift in therapeutic strategies. This insight could lead to the development of more effective immunotherapies tailored to the unique immune landscape of thyroid cancer.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor ongoing trials targeting LAG3 and TIGIT in thyroid cancer, as well as any new immunotherapeutic agents emerging from this research.
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.